CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026

Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral components Demonstrating CREATE's leadership in in vivo immune cell engineering across T cells, NK cells, and myeloid cells CAMBRIDGE, Mass., April 17, 2026...